Background: Fluoroquinolones (FQs) are used for drug-susceptible tuberculosis (TB) in patients unable to tolerate first-line agents. Current trials are also investigating these drugs in empiric first-line TB therapy, to improve outcomes and allow for shortened treatment regimens. Widespread FQ use in the community has resulted in FQ resistance in many microorganisms, including Mycobacterium tuberculosis. Despite this, FQ drug susceptibility testing (DST) is rarely performed in non-multidrug-resistant TB (non-MDR-TB).
Methods: We conducted a 1-year surveillance study of FQ resistance on all MTB isolates from New South Wales (NSW), Australia. In addition, we performed a literature review of previous studies assessing FQ resistance in non-MDR-TB to summarize the global extent of this resistance pattern.
Results: Two (0.6%) out of 357 MTB isolates from NSW were found to be FQ-resistant. One isolate was an MDR strain (11% of all MDR-TB). The other was isoniazid-monoresistant (0.3% of all non-MDR-TB). Eleven studies from 10 countries had performed FQ resistance surveillance on non-MDR-TB. In the majority of these studies, FQ resistance was found to be low (mean 1%; 95% confidence interval 0.2-2%).
Conclusions: FQ resistance in non-MDR-TB is uncommon in NSW, Australia. The existing global evidence suggests that FQ resistance remains largely confined to MDR-TB strains. In the majority of TB endemic regions, however, FQ resistance in non-MDR-TB has not been assessed. Knowledge of the prevalence of FQ resistance in MTB is essential to guide the rational use of these drugs, including their feasibility as first-line agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijid.2014.03.1388 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk assessment and transmission of fluoroquinolone resistance in drug-resistant pulmonary tuberculosis: a retrospective genomic epidemiology study.
Sci Rep
August 2024
State TB Training and Demonstration Centre, Intermediate Reference Laboratory, Government Hospital for Chest Diseases, Puducherry, India.
Article Synopsis
- Fluoroquinolone resistance poses a significant challenge in treating Multidrug-Resistant Tuberculosis (MDR-TB), with notable resistance rates of 33% in MDR-TB and 16.5% in Rifampicin-Resistant TB.
- The most common mutation linked to fluoroquinolone resistance was found in the gyrA gene, specifically D94G, and there was a notable prevalence of pre-XDR-TB and Extensively Drug-Resistant TB among MDR-TB isolates.
- The study emphasizes the urgent need for rapid diagnosis of fluoroquinolone resistance to improve treatment outcomes and control resistance spread in high-prevalence areas.
Costs of non-multidrug-resistant pulmonary tuberculosis and of preventive treatment in Germany - An update.
J Clin Tuberc Other Mycobact Dis
August 2024
Institute for Health Service Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Background: Only 4076 new cases of tuberculosis (TB) were reported in Germany in 2022; of those 184 were multidrug-resistant TB (MDR-/RR-TB).
Methods: Based on the current therapy guidelines of the German Central Committee against Tuberculosis and most recent renumeration data of the Statutory Health Insurances (SHI), this study estimates the mean in- and outpatient costs per adult infectious pulmonary non-MDR-TB patient, together with costs arising from Rifampicin (RIF)-based short-course options of tuberculosis preventive treatment (TPT) of their close contacts.
Results: From the insurance perspective, the mean inpatient cost (rounded) per adult case was 6138 EUR (SD±2810 EUR) for standard therapy; the cost of primary outpatient treatment only amounted to 1930 EUR and the cost of outpatient treatment post-hospital to 1093 EUR.
Epidemiology and antimicrobial resistance of spp. in the United Arab Emirates: a retrospective analysis of 12 years of national antimicrobial resistance surveillance data.
Front Public Health
July 2024
Department of Pathology and Infectious Diseases, Khalifa University, Abu Dhabi, United Arab Emirates.
Article Synopsis
- * A 12-year study in the UAE analyzed over 8,000 non-duplicate MTB complex isolates, primarily from respiratory samples, revealing that most patients were non-nationals from Asian countries, particularly India and Pakistan.
- * The study found low levels of drug resistance, with 2.8% of MTB isolates being rifampicin-resistant and a slight upward trend in resistance observed over the years.
Risk factors for multidrug-resistant tuberculosis in the Central African Republic: A case-control study.
J Infect Public Health
September 2023
National Reference Centre for Sexually Transmitted Diseases and Antiretroviral Therapy, Bangui, Central African Republic; Unit for Research and Intervention in Public Health, Department of Public Health, Faculty of Health Sciences, Bangui, Central African Republic.
Background: The emergence and spread of multidrug-resistant tuberculosis (MDR-TB) presents a challenge to the "End TB by 2035" strategy. This study aimed to identify the risk factors associated with MDR-TB in patients admitted to the pneumo-physiology clinic of the National University Hospital of Bangui in Central African Republic.
Methods: This was a "retrospective" chart review study.
Molecular Detection of Ofloxacin and Kanamycin Resistance in Patients with MDR and Non-MDR TB from Suburban Districts in Hangzhou, China, 2019-2020.
Biomed Environ Sci
May 2022
Department of TB Control and Prevention, Hangzhou Center for Disease Control and Prevention, Hangzhou 310021, Zhejiang, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!